Virus-Like Particle Carriers for Competitive Pathogen Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and medications for pathogens like SARS-CoV-2, influenza, rhinoviruses, and noroviruses are time-consuming to develop, have limited efficacy, and can cause adverse reactions, while antibiotics face resistance issues, necessitating a proactive, minimally invasive approach to prevent pathogen spread.
Innovation Solution
Development of nano- and micromaterial-based carriers that mimic pathogens to competitively inhibit binding to host cells, deliver immune-stimulating agents, and encapsulate or immobilize pathogens, using biocompatible materials like mesoporous silica nanoparticles and lipid-based micelles to target and block receptor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines and medications are used to treat pathogens, then pathogen infection can be addressed, but development time is time-consuming and efficacy is limited
Solution Approach 1:
The patent applies preliminary action by creating virus-like particles (VLPs) that mimic pathogen structures before actual infection occurs. These VLPs are designed to bind to host cell receptors and block pathogen entry in advance, providing proactive protection rather than reactive treatment after infection establishes.
Solution Approach 2:
The patent uses copying by creating artificial virus-like particles that replicate the structural characteristics of real pathogens without containing their genetic material. These VLPs copy the surface proteins and morphology of viruses like SARS-CoV-2, influenza, and norovirus, allowing the immune system to recognize and respond to pathogen features without exposure to actual infectious agents.
2Reliability
If conventional vaccines and medications are used, then pathogen infection can be addressed, but adverse reactions occur
Solution Approach 1:
The patent applies the extraction principle by separating the harmful genetic material from the beneficial structural components. The VLPs contain only the structural proteins and surface features necessary for immune recognition, while excluding the viral genome and replicative machinery. This extraction eliminates the risk of viral replication and adverse reactions while maintaining the protective function.
Solution Approach 2:
The patent uses disposable VLPs that are designed to be degraded and eliminated by the host immune system after providing temporary protection. These artificial particles serve as a short-term blocking mechanism that can be rapidly cleared from the body, avoiding the long-term persistence and potential harm associated with conventional vaccines and medications.
3Reliability
If antibiotics are used to treat infections, then bacterial infections can be addressed, but resistance develops
Solution Approach 1:
The patent replaces the chemical mechanism of antibiotics with a physical blocking mechanism. Instead of using chemical substances that can be metabolized and lead to resistance, the VLPs provide a physical barrier that binds to host cell receptors and prevents pathogen attachment. This mechanical blocking approach does not involve chemical selection pressure that drives resistance development.
4Reliability
If nano- and micromaterial-based carriers are developed to mimic pathogens, then pathogen binding can be blocked, but device complexity increases
Solution Approach 1:
The patent applies parameter changes by adjusting the size, shape, and surface properties of the VLPs to match specific pathogens. The particles are engineered with controlled dimensions (nanometer to micrometer range) and surface charge characteristics that optimize binding to host cell receptors. These parameter optimizations enable effective pathogen blocking while maintaining relatively simple particle structures.
Solution Approach 2:
The patent achieves universality by designing a platform approach where a single VLP generation system can produce particles targeting multiple different pathogens by simply changing the surface protein composition. This multi-functional platform reduces overall system complexity compared to developing separate specialized systems for each pathogen type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces pathogen binding and replication risks, minimizes infection spread, and provides targeted treatment with reduced side effects, enhancing host immune response and facilitating pathogen elimination.
Implementation Method 1
binding of the carrier to at least one of the target areas of cell structures of the host is configured to at least partially block the pathogen from binding to said target areas as a result of competitive inhibition
Implementation Method 2
the surface features at least partially physically mimic naturally-occurring protrusions of the pathogen
Implementation Method 3
the binding sites are configured to at least partially mimic binding sites of the cell structures of the host, wherein the binding sites are recognizable by the pathogen and are able to be bound by the pathogen, thereby at least partially immobilizing the pathogen
Data Source
AI summary
According to some embodiments, a carrier for reducing a likelihood of a pathogen binding to cell structures of a host comprises a core, surface features extending from an exterior surface of the core, wherein the surface features are configured to bind to target areas of cell structures of the host to at least partially block the pathogen from binding to said target areas as a result of competitive inhibition, and a plurality of binding sites along the exterior surface, wherein the binding sites are configured to attract at least one portion of the pathogen, wherein the binding sites are recognizable by the pathogen and are able to be bound by the pathogen, thereby at least partially immobilizing the pathogen and reducing the likelihood of the pathogen binding to target areas of cell structures of the host.